• Vertex Pharmaceuticals for other rare respiratory diseases, but still in clinical trials.
• BioMarin Pharmaceutical focused purely on rare respiratory diseases, currently clinical-stage.

• Molgradex: An investigational inhaled drug (recombinant human GM-CSF) currently in development for treating autoimmune pulmonary alveolar proteinosis (aPAP).

Savara (SVRA) is a biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. As a development-stage company, Savara does not currently have any commercialized products generating significant revenue from product sales.

Therefore, Savara does not currently have "major customers" in the traditional sense of entities purchasing its commercial products. Its current revenue is primarily derived from sources such as grants, collaborations, and other development activities.

However, should Savara's lead product candidate, Molgradex, receive regulatory approval and be commercialized, the company would primarily sell its products to other companies within the healthcare supply chain. These potential future major customers would typically include:

• Pharmaceutical Wholesalers: These large distributors purchase pharmaceutical products from manufacturers and then distribute them to hospitals, retail pharmacies, government agencies, and other healthcare providers across the country. Examples of such public companies include:
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corporation (ABC)
  • Cardinal Health, Inc. (CAH)
• Specialty Pharmacies and Distributors: For drugs treating rare or complex conditions, manufacturers often partner with specialty pharmacies and distributors. These entities are equipped to handle unique storage, delivery, and patient support requirements.

• Siegfried Holding AG (SFZN.VX)
• Recipharm AB (RECI B.ST)
• Catalent, Inc. (CTLT)

Matthew Pauls, Chair and Chief Executive Officer

Mr. Pauls has served as Savara's Chair and Chief Executive Officer since 2020. He founded Spartan Biopharma Insights, LLC. Previously, he was President and Chief Executive Officer of Strongbridge Biopharma plc, which he took public via an IPO on the NASDAQ. He also served on the Board of Directors of Zyla Life Sciences, which merged with Assertio Therapeutics in 2020, and was Chair of the Board of Directors of Mast Therapeutics, with which Savara completed a reverse merger. His career also includes leadership positions at Insmed, Inc., Shire Pharmaceuticals, Bristol-Myers Squibb, and Johnson & Johnson.

Dave Lowrance, Chief Financial and Administrative Officer

Mr. Lowrance has served as Savara's Chief Financial and Administrative Officer since December 2022, and as Chief Financial Officer since November 2016. Prior to joining Savara, he was the Chief Financial Officer and Treasurer of Edgemont Pharmaceuticals. He also previously held Chief Financial Officer positions at Acucela and Cumberland Pharmaceuticals.

Robert Lutz, Chief Operating Officer

Mr. Lutz joined Savara as Chief Operating Officer in February 2023. He brings nearly two decades of operational leadership experience in the pharmaceutical industry, including business development, capital markets, and finance strategy. His previous roles include Chief Financial and Business Officer of iBio, Inc., and Chief Financial Officer of Strongbridge Biopharma plc.

Anne Erickson, Chief Business Officer

Ms. Erickson has served as Savara's Chief Business Officer since August 2023. She is responsible for Investor Relations, Corporate Affairs, Project Management, Advocacy Relations & Patient Engagement, and Medical Affairs teams, and leads corporate strategy projects. Prior to Savara, she held leadership roles at Mirati Therapeutics, Halozyme, Pfizer, and Ogilvy. She also led the Clinical Operations Team for the IMPALA-2 trial at Savara.

Dr. Sara Wasfi, Chief Medical Officer

Dr. Wasfi was appointed Chief Medical Officer in October 2025. She has over two decades of industry and healthcare experience in clinical research and drug development. Her background includes roles of increasing responsibility at Amicus Therapeutics, Johnson & Johnson, and Merck.

Savara Inc.'s (SVRA) primary product is Molgradex (molgramostim), an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is in Phase 3 clinical development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).

Addressable Market Sizes for Molgradex (molgramostim) for Autoimmune Pulmonary Alveolar Proteinosis (aPAP):

• The estimated global commercial opportunity for molgramostim in aPAP is projected to exceed $1 billion.
• In 2023, the market size for aPAP in the United States was approximately $120 million.
• The combined market size for aPAP in the EU4 (Germany, France, Italy, Spain) and the United Kingdom was approximately $35 million in 2023.
• The overall aPAP market size across the seven major markets (United States, EU5, and Japan) was valued at approximately $220 million in 2023, with anticipated significant growth through 2034.
• The estimated true prevalence of aPAP in the U.S., EU, and Japan is between 15,000 and 18,000 patients, with 5,000 to 7,000 currently diagnosed patients in these regions.
• Specifically for the U.S., the aPAP patient population is estimated to be around 2,317 patients (based on 7 cases per million in 2021).
• Annual revenue for Molgradex in the U.S. is projected to reach $98 million by 2037.

1. Commercialization of Molbreevi (molgramostim) for Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Savara completed the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Molbreevi as a treatment for aPAP in the first half of 2025, with a Priority Review requested. The company is preparing for a potential commercial launch in early 2026. Analysts project peak annual U.S. sales for Molbreevi to reach $962 million and worldwide peak sales of approximately $1.6 billion, driven by a high anticipated launch list price of $425,000. The drug has received Breakthrough Therapy Designation and Orphan Drug Designation, indicating a high unmet medical need and reduced competition.
2. Expansion of Molgramostim into New Indications: Beyond aPAP, Molgradex (molgramostim) is in Phase 2a development for nontuberculous mycobacteria (NTM) lung infection and is being prepared for Phase 2a development in cystic fibrosis (CF). Successful progression and eventual approval in these additional orphan lung diseases would significantly broaden the market opportunity for molgramostim.
3. Pipeline Expansion through Acquisitions and Partnerships: Savara's strategy includes expanding its pipeline through indication expansion, strategic development partnerships, and product acquisitions. The recent acquisition of aerosolized amikacin/fosfomycin, a Phase 2 ready proprietary combination antibiotic, exemplifies this strategy and could contribute to future revenue growth as it advances through clinical development.

Share Issuance

• In October 2025, Savara completed an underwritten public offering of common stock and pre-funded warrants, generating approximately $149.5 million in gross proceeds.
• The proceeds from this offering are designated for general corporate purposes, including funding the clinical development and regulatory approval efforts for MOLBREEVI, investing in commercialization infrastructure, and preparing for commercial launches in the U.S. and EU.

Inbound Investments

• On October 29, 2025, Savara entered into a $75 million non-dilutive royalty funding agreement with RTW Investments, LP, contingent on FDA approval of MOLBREEVI by March 31, 2027.
• In return for the $75 million, RTW will receive tiered single-digit royalty payments on U.S. net sales of MOLBREEVI, up to a cap of $187.5 million in total payments.
• On March 26, 2025, Savara secured a loan and security agreement with Hercules Capital, Inc., for up to $200 million, with an initial $30 million funded to refinance existing debt.

Capital Expenditures

• Savara's capital expenditures were $0.01 million in 2022, $0.30 million in 2023, and $0.03 million in 2024.
• The company reported negative free cash flow of -$57.17 million, reflecting substantial ongoing expenditures primarily in clinical trial endeavors and research and development as it is in an "investment-heavy phase."